Abstract: The present invention provides an artificial dressing and a use of the artificial dressing for promoting wound healing. The artificial dressing includes a gelatin and a fungal extract.

Abstract: Nitric oxide-releasing materials, methods of making nitric oxide-releasing materials, and uses of nitric oxide-releasing materials are provided. The nitric oxide-releasing materials include a mesoporous silica core and an outer surface having a plurality of nitric oxide donors. In an exemplary aspects, the nitric oxide-releasing material includes a mesoporous diatomaceous earth core, and an outer surface having a plurality of S-nitroso-N-acetyl-penicillamine groups covalently attached thereto. Uses of the nitric oxide-releasing materials can include coatings for medical devices such as catheters, grafts, and stents; wound gauzes; acne medications; and antiseptic mouthwashes; among others.

Abstract: A bandage device having a flexible body with a plurality of fluid reservoirs thereon each containing a liquid topical treatment therein. Mixing areas located between the respective fluid reservoirs on the bandage provide for mixing and formation of liquid mixtures of the respective liquid topical treatments flowing thereto from the respective fluid reservoirs located adjacent thereto. The liquid mixtures from the mixing areas when absorbed through the skin of a wearer of the bandage yield an enhanced synergistic effect exceeding that of the individual fluids such medications or essential oils.

Abstract: Methods are disclosed including methods for crystallizing a material such as a drug. An example method may include combining a nucleation initiator, a surfactant solution, and an amorphous form of a drug to form a drug precursor dispersion/suspension. The method may also include incubating the drug precursor dispersion/suspension to allow the drug to convert from the amorphous form to a crystalline form.

Abstract: The present invention describes a process to isomerize industrial hemp derived Cannabidiol (CBD) to a pure ?8-tetrahydrocannabinol (?8-THC) extract. This procedure will produce ?8-tetrahydrocannabinol that is essentially free from any detectable levels of ?9-tetrahydrocannabinol (?9-THC). Included in this filing are methods and processes to scale the reaction from the lab to process to large scale manufacturing. Additionally, the resulting extract from said methods and processes consists of higher purity than previously reported in the art and greater efficiency compared to prior art.

Abstract: The present invention concerns a transdermal therapeutic system, comprising a backing layer, which is not permeable for the active ingredient, and a matrix layer on one side of the backing layer, wherein the matrix layer contains at least one pressure sensitive adhesive and ketamine or a pharmaceutically acceptable salt or solvate thereof, wherein the at least one pressure sensitive adhesive has free hydroxyl groups, as well as its use as medicament, in particular for the treatment of depression and pain.

Abstract: The present invention relates to a multi-layered composite garment material comprising at least a fabric layer and a functionalized adhesive sheet layer. The present invention also relates to a functionalized adhesive sheet or film comprising 3D adhesive structures embossed on the sheet or film. The sheet or film can be used to bind multiple garment layers while maintaining or enhancing the characteristics of the individual garment layers.

Abstract: Various adhesive compositions are described which may optionally comprise one or more active agents such as pharmaceutical agents. The incorporation of one or more absorbents in combination with one or more crystallization inhibitors improves adhesive characteristics of the compositions. Also described are related methods of improving adhesive characteristics of adhesive compositions with the use of a combination of absorbent and inhibitor. Also described are related methods of using the compositions and articles incorporating such compositions.

Abstract: The invention relates to a transdermal therapeutic system for the controlled release of water-soluble pharmaceutical active ingredients from an aqueous phase, comprising an occlusive back layer, a central device facing the skin for releasing the agent, an adhesive layer concentrically surrounding the dispensing device and a removable protective film. Said device is made from a stationary solid phase and a liquid phase containing the active ingredient in aqueous solution, the solid phase being formed from a solid with a fleecy or spongy structure.

Abstract: The invention relates to a medical product for a fastening duration of at least 7 days having good skin compatibility. The medical product includes a central adhesive compartment (3) and an over-patch. The over-patch is free of active ingredients and is formed from a water-vapor-permeable back layer (1) and an adhesive polymer layer (2) that is free of active ingredients. The invention further relates to a method for the production of the foregoing medical product, and to kits of parts containing laminates of layers 1 and 2.

Abstract: The present invention relates to a method and corresponding apparatus for just in time mixing of a solid or powdered formulation and its subsequent delivery to a biological body. In some embodiments, a powdered formulation is maintained in a first chamber of a plurality of chambers. A plurality of electromagnetic actuators are in communication with the plurality of chambers. The actuators, when activated, generate a pressure within at least the first chamber. The pressure results in mixing of the powdered formulation and a diluent in time for delivering into the biological body.

Abstract: Aspects of the invention include extended transdermal delivery devices for delivering buprenorphine to a subject for an extended period of time, where the transdermal delivery devices include buprenorphine, an ?-hydroxy acid and a pressure sensitive adhesive. In certain instances, buprenorphine, ?-hydroxy acid and the pressure sensitive adhesive are provided as a single matrix layer formulation. Also provided are methods of using the subject extended transdermal delivery devices, as well as kits containing the extended transdermal delivery device.

Abstract: The present disclosure describes methods of treating cellulosic materials with compositions that allow greater retention of inorganic particles on cellulosic substrates. The methods as disclosed provide combining saccharide fatty acid esters (SFAE) with such inorganic particles and applying such combinations on cellulosic materials to eliminate or reduce the use of retention aids or binders for filler in the paper making process. Compositions comprising such combinations of SFAE and inorganic particles are also disclosed.

Abstract: A transdermal topical anesthetic formulation, which can be used to ameliorate or inhibit pain, has been developed. In the preferred embodiment, the topical anesthetic is a local anesthetic such as lidocaine, most preferably lidocaine free-base in a gel, and the dosage of the local anesthetic is effective in the painful area or immediately adjacent areas, to ameliorate or eliminate the pain. High concentration of local anesthetic in solution in the carrier is used to drive rapid release and uptake of the drug. Relief is typically obtained for a period of several hours.

Abstract: An apparatus and method deliver fluid treatments to a targeted plant. The apparatus comprises a two-piece protective shell joined on one side by a spring-hinge. When the two piece outer protective shell is open, a fluid treatment is applied to a liquid retaining material within the protective shell. A portion of a targeted plant is placed within the open outer protective shell. The two piece outer protective shell is then closed, creating a sealed containment environment that is immediately protected from environmental disturbance, prevents distribution of fluid treatment to non-treated plant materials, and will retain, store, and prevent leakage of the fluid treatment. The closed outer protective shell also clasps the plant portion, forcing contact of the target plant portion with fluid treatment residing on and within the liquid retaining material. The apparatus remains attached to the targeted plant while the fluid treatment is absorbed through systemic plant processes.

Abstract: A patch preparation which can produce the effect for preventing any problems due to the misuse of the patch preparation, includes a support and a plaster wherein the plaster includes a) an aliphatic compound with hydrophilic group which is in solid state at room temperature, b) a non-aqueous adhesive, and c) a solvent with a vapor pressure of 1 kPa or more at 20° C.

Abstract: Device comprising polyurethane material for indicating pH at a locus, preferably as indication of presence of microbes, comprising a polyurethane network having immobilised therein one or more hydrophilic copolymers, the or each said copolymer comprising: hydrophilic monomer; and indicator monomer, which provides an indication in response to a change in hydrophilic state of said hydrophilic monomer and/or copolymer; characterised in that the or each copolymer further comprises one or a plurality of ionisable groups or moieties or polymerisable monomers having one or more characteristic pKa values in the range 5 to 10 and which are responsive to pH at the locus in the range pH 5 to pH 10 and in that hydrophilic state of hydrophilic copolymer is dependent on ionisation of said ionisable groups, moieties or monomers; kit and device comprising the material and process for preparation thereof; and use in detecting or sensing microbes or pH.

Abstract: The present invention provides a patch comprising a backing layer and an adhesive agent layer, wherein the adhesive agent layer is non-aqueous, the adhesive agent layer contains nonylic acid vanillylamide and aluminum hydroxide, a content of nonylic acid vanillylamide in the adhesive agent layer is 0.01 to 0.025% by mass based on a total mass of the adhesive agent layer, a content of aluminum hydroxide in the adhesive agent layer is 0.55 to 1.5% by mass based on the total mass of the adhesive agent layer, and a mass ratio of the content of nonylic acid vanillylamide to the content of aluminum hydroxide ((content of nonylic acid vanillylamide):(content of aluminum hydroxide)) in the adhesive agent layer is 1:27 to 1:150.

Abstract: The present invention provides for a method of improving the release of non-steroidal anti-inflammatory drugs (NSAIDs) from a plaster or bandage comprising an adhesive layer with a pharmaceutically acceptable NSAID together with heparin or a heparinoid. The invention also provides for methods of reducing muscle hyperalgesia in subjects without spontaneous pain.

Abstract: The present invention provides for a method of improving the release of non-steroidal anti-inflammatory drugs (NSAIDs) from a plaster or bandage comprising an adhesive layer with a pharmaceutically acceptable NSAID together with heparin or a heparinoid. The invention also provides for methods of reducing muscle hyperalgesia in subjects without spontaneous pain.

Abstract: A bandage device having a flexible body with a plurality of fluid reservoirs thereon each containing a liquid topical treatment therein. Mixing areas located between the respective fluid reservoirs on the bandage provide for mixing and formation of liquid mixtures of the respective liquid topical treatments flowing thereto from the respective fluid reservoirs located adjacent thereto. The liquid mixtures from the mixing areas when absorbed through the skin of a wearer of the bandage yield an enhanced synergistic effect exceeding that of the individual fluids such medications or essential oils.

Abstract: Provided herein is a water- and sweat-resistant transdermal drug delivery system for application to the skin of a mammal that comprises a patch having a diameter between 1 and 8 cm in length and a surface area between 4 and 8 cm2. Also provided are methods of producing the transdermal drug delivery system and methods of treatment comprising the use of the transdermal drug delivery system.

Abstract: The present invention relates to the combination of spirulina and palmitoylethanolamide (PEA) and/or pharmaceutically acceptable derivates or salts thereof, pharmaceutical formulations comprising the combination of spirulina and PEA and/or pharmaceutically acceptable derivates or salts thereof, optionally together with at least one physiologically acceptable excipient, and the use of the combination of spirulina and PEA and/or pharmaceutically acceptable derivates or salts thereof and formulations which include the said combination, for use in the prevention and/or treatment of tissue hyperactivation states, in the prevention and/or treatment of inflammatory pathologies, in the prevention and/or treatment of alterations in cardiac and/or coronary tissue, in the prevention and/or treatment of alterations in the vascular tissue, in the prevention and/or treatment of ophthalmic pathologies, preferably in the prevention and/or treatment of macular degeneration pathologies and glaucoma, in the prevention and/or tr

Abstract: Provided is a transdermal absorption preparation having superior drug skin permeability, which can uniformly disperse the drug in the preparation and maintain the uniform dispersion state of the drug. A transdermal absorption preparation having a plaster layer containing a drug, a polymer and a pH adjuster, in which the aforementioned polymer contains a polymer having a particular glass transition temperature of 30° C.-200° C., and the surface of the plaster layer has a pH of 6.7-10.0.

Abstract: A binder layer for a laminated wound dressing is brought into contact with a sheet coated with a pattern-coated adhesive sheet. As the binder layer is in contact with the pattern-coated adhesive sheet, a series of closed-loop cuts are made in the binder layer. The closed-loop cuts are made in such a way that the material enclosed by each closed loop is substantially physically separated from the remainder of the binder layer. Then the binder layer is moved away from the pattern-coated adhesive sheet, so that the binder layer and the pattern-coated adhesive sheet are no longer in contact. When the binder layer and the pattern-coated adhesive sheet are moved apart, the material enclosed in the closed-loop cuts—i.e., the cut waste fragments—are retained on the pattern-coated adhesive sheet, ensuring that the binder layer includes a series of cleared perforations.

Abstract: Disclosed is a hydrophilic dressing (200) having appropriate mechanical strength, comprising a composite material (100, 220) and a film (210). The composite material (100, 220) comprises a hydrophilic substrate material (110) and a compound (120) that promotes wound healing, wherein the hydrophilic substrate material (110) is a reaction product of a hydrophilic polymer, wherein the hydrophilic polymer comprises a hydrophilic monomer, a cross-linking agent and an inorganic silicon-oxygen compound, wherein the compound (120) that promotes wound healing is distributed in the hydrophilic substrate material (110).

Abstract: A compound for treatment of pain comprising a single multivalent/multifunctional ligand with agonist activity at opioid receptors and with antagonist activity at NK-1 receptors, joined by a linker. Also disclosed is a pharmaceutical compound comprising the above compound in a pharmaceutically acceptable carrier.

Abstract: A pharmaceutical composition and a health functional food including an oat extract as an effective ingredient for prevention or treatment of neurodegenerative disease. More specifically, the present invention provides a pharmaceutical composition and a health functional food including an oat extract such as avenanthramide C or a derivative thereof, for example, avenanthramide methyl ester as an effective ingredient for prevention or treatment of Alzheimer's disease.

Abstract: Disclosed herein are compositions and methods for topical delivery of mTOR inhibitors. In one embodiment, an anhydrous composition includes one or more mTOR inhibitors, one or more solvents, one or more gelling agents, and one or more antioxidants. Also disclosed herein are methods to treat skin disorders using such compositions.

Abstract: Nitric oxide-releasing materials, methods of making nitric oxide-releasing materials, and uses of nitric oxide-releasing materials are provided. The nitric oxide-releasing materials include a mesoporous silica core and an outer surface having a plurality of nitric oxide donors. In an exemplary aspects, the nitric oxide-releasing material includes a mesoporous diatomaceous earth core, and an outer surface having a plurality of S-nitroso-N-acetyl-penicillamine groups covalently attached thereto. Uses of the nitric oxide-releasing materials can include coatings for medical devices such as catheters, grafts, and stents; wound gauzes; acne medications; and antiseptic mouthwashes; among others.

Abstract: Disclosed is an oral care device, comprising: an elongate strip having a major surface; and first and second tabs respectively extending from first and second portions of the major surface. Each of the first and second tabs is movable relative to the strip between a storage position and an operative position. The strip holds an oral care agent at the major surface of the strip. Also disclosed is a stack of the oral care devices located in an airtight package.

Abstract: Enteric elastomers and related methods are generally provided. In some embodiments, the enteric elastomer is a polymer composite. Certain embodiments comprise a polymer composite in which hydrogen bonds within two carboxyl group-containing polymers cross-link the polymer networks into an elastic and pH-responsive polymer composite. Advantageously, this polymer composite has the capacity of being stable and elastic in an acidic environment such as that of the stomach but can be dissolved in a neutral pH environment such as that of the small and large intestines. In some embodiments, the polymer composites described herein comprise a mixture of two or more polymers with carboxyl functionality such that the two or more polymers form hydrogen bonds. In certain embodiments, the polymer composite has both enteric and elastic properties.

Abstract: An orally administered dosage form that facilitates delivery of an agent locally in the buccal cavity for a sustained period of time includes mucoadhesive particles that are made of at least a mucoadhesive material combined with the agent, and which are dispersed in a disintegrating film. The dosage form is capable of delivering an agent to a patient at the desired oral mucosa site over an extended period of time while reducing patient discomfort or annoyance associated with conventional sustained release mucoadhesive films that must reside on the oral mucosa during the period of sustained release.

Abstract: The patch of the present invention comprises a backing layer and an adhesive layer laminated on the backing layer, wherein a water vapor transmission rate of the backing layer is 400 g/m2·24 hours or more, and the adhesive layer comprises a drug, dimethylsulfoxide and an adhesive. Such a patch does not fall off easily even after long wear.

Abstract: The present invention relates to a transdermal therapeutic system for administration of an active ingredient and a process for the preparation thereof. The transdermal therapeutic system comprises an overtape with two adhesive layers.

Abstract: A method for creating a multi-antigen patch, comprising providing one or more transdermal patch sheets having a plurality of single dose transdermal patches residing thereon, wherein each one of the plurality of single dose transdermal patches includes an antigen at a particular dilution level disposed within a carrier, removing one or more of the plurality of single dose transdermal patches from the one or more transdermal patch sheets, adhering the one or more of the plurality of single dose transdermal patches to a backing, wherein the backing allows for multiple single dose transdermal patches to be adjacently adhered thereon, and covering the plurality of transdermal patches adhered to the backing with a peelable release liner.

Abstract: An object of the present invention is to provide a self-assembly composition for pattern formation, which is capable of forming a favorable phase-separated structure even in the case of forming a large size pattern. In addition, another object of the present invention is to provide a self-assembly composition for pattern formation, which is capable of forming a pattern by a simple process, with no need for preparation of a under layer, etc., upon formation of a fine pattern structure. The present invention relates to a self-assembly composition for pattern formation, which comprises a block copolymer comprising a polymerization unit (a) comprising two or more units consisting of at least one type selected from a glucose unit and a xylose unit, and a polymerization unit (b) comprising two or more units consisting of at least one type selected from an aromatic ring-containing unit, a silicon-containing unit and a metal-containing unit.

Abstract: Certain exemplary embodiments can provide a system, machine, device, manufacture, circuit, composition of matter, and/or user interface adapted for and/or resulting from, and/or a method and/or machine-readable medium comprising machine-implementable instructions for, activities that can comprise and/or relate to, controlling delivery of a transdermally-delivered medication, certain embodiments including a flux controller.

Abstract: An apparatus for hand protection includes a flexible sheet that extends from a first end to a second end of the flexible sheet along a length thereof. Adhesive material is located on one side of the flexible sheet. A backing layer is on the adhesive material. The flexible sheet includes at least one finger opening closer to the first end than to the second end. A method enables a flexible sheet with adhesive material thereon to be applied to a person's hands. Fingers are inserted through one or more finger openings. The backing layer is removed. The flexible sheet is adhered to the person's hand.

Abstract: A method for producing a gel patch comprising an adhesive mass layer on a backing fabric, comprising a step of applying a composition comprising a physiologically active substance, a water-soluble polymer, glycerin, and water to the backing fabric to form the adhesive mass layer, wherein a loss tangent of the composition in dynamic viscoelasticity measurement at 1 Hz at a time of application to the backing fabric is 0.75 to 1.

Abstract: Pharmaceutical formulations and methods for the topical or transdermal delivery of 1isobutyl-1H-imidazo[4,5-c]-quinolin-4-amine or 1-(2-methylpropyl)-1H-imidazo[4,5 c]quinolin-4-amine, i.e., imiquimod, to treat genital/perianal warts with shorter durations of therapy than currently prescribed for the commercially available for Aldara® 5% imiquimod cream, as now approved by the U.S. Food & Drug Administration (“FDA”), are disclosed and described. More specifically, lower dosage strength imiquimod formulations to deliver an efficacious dose of imiquimod for treating genital/perianal warts with an acceptable safety profile and dosing regimens that are shorter and more convenient for patient use than the dosing regimen currently approved by the U.S. Food & Drug Administration (“FDA”) for Aldara® 5% imiquimod cream to treat genital/perianal warts are also disclosed and described.

Abstract: In embodiments, the present invention relates to a method of producing a multilayered printed item, comprising: (a) providing a coating of curable composition comprising a polymer powder, at least one plasticizer, and at least one monomer and/or oligomer, onto the substrate or a thereon previously applied layer or coating; (b) heating the curable coating composition to a temperature of about 70-120° C., to provide a gelled curable coating; (c) providing a coating of curable composition comprising a polymer powder, at least one plasticizer, and at least one monomer and/or oligomer, onto the previously applied layer or coating; (d) heating the other curable as above, to provide second gelled curable coating; (e) before crosslinking is performed, the multilayer-coated substrate formed is heated to a temperature of about 130-160° C.; and (f) crosslinking the heated multilayer-coated substrate, by irradiation and/or subjection to heat at a temperature of about 165-190° C.

Abstract: Devices for guided tissue regeneration (GTR) include a matrix of chitosan and mutable collagenous tissue (MCT) wherein the chitosan is electrostatically bonded to the MCT to form MCT-chitosan composite material. The MCT can be isolated from invertebrate marine organisms, such as sponges, jellyfish, mollusks and echinoderms. The MCT-chitosan composite material can be formulated as a biofilm, a 3D-sponge, a hydrogel, or as an electrospun nanofiber, or the MCT-chitosan composite material can coat a biomaterial surface. The devices can include wound dressings and tissue sponges, including 3D sponges. Applications include tissue engineering and wound healing, as well as burns and other related guided tissue regeneration applications. MCT and MCT-chitosan composite material, contained in a pharmaceutically acceptable topical carrier, also has cosmeceutical applications, for treating scars, as well as skin discoloration and various pigmentation issues, including melasma/chloasma.

Abstract: The present invention provides for a method of improving the release of non-steroidal anti-inflammatory drugs (NSAIDs) from a plaster or bandage comprising an adhesive layer with a pharmaceutically acceptable NSAID together with heparin or a heparinoid. The invention also provides for methods of reducing muscle hyperalgesia in subjects without spontaneous pain.

Abstract: A transdermal dosing unit may include a first segment having a first pharmaceutical in a first reservoir, a first releasing compound, and a first adhesive component, a second segment removably connected to the first segment, the second segment having a second pharmaceutical in a second reservoir, a second releasing component, and a second adhesive component, and a backing component. The transdermal dosing unit may further include additional segments, and may include a perforated section between each segment. The first adhesive component may have a first adhesion strength, and the second adhesive component may have a second adhesion strength that is either different from or approximately equal to the first adhesion strength. A method of titrating a dose of such a transdermal dosing unit may include applying the transdermal dosing unit to a subject, and removing the first segment while leaving the second segment on the subject.

Abstract: Compositions and methods for improving skin health and skin barrier function. Specifically, topical administration of compositions comprising low dose formulations of ambroxol can be used to improve skin barrier function.

Abstract: The present invention provides for a method of improving the release of non-steroidal anti-inflammatory drugs (NSAIDs) from a plaster or bandage comprising an adhesive layer with a pharmaceutically acceptable NSAID together with heparin or a heparinoid. The invention also provides for methods of reducing muscle hyperalgesia in subjects without spontaneous pain.

Abstract: Certain exemplary embodiments can provide a system, machine, device, manufacture, circuit, composition of matter, and/or user interface adapted for and/or resulting from, and/or a method and/or machine-readable medium comprising machine-implementable instructions for, activities that can comprise and/or relate to, controlling delivery of a transdermally-delivered medication, certain embodiments including a flux controller.

Abstract: A system for delivering energy to an isolated part of a mammalian body includes an electrically powered patch and a self-supporting adhesive film. The patch has a major surface and comprises a matrix of at least one flexible, biocompatible material which is capable of conforming to the isolated body part. The self-supporting adhesive film has a first non-tacky surface arranged and configured for releasable attachment to the patch and a second tacky surface, opposite the first surface, for adhesive attachment to the isolated body part. The releasable attachment between the self-supporting adhesive film and the electrically powered patch has a lower strength than the adhesive attachment between the film and the isolated body part. Thus, during use the electrically powered patch is removable from the self-supporting adhesive film while leaving the self-supporting adhesive film adhered to the isolated body part.

Abstract: The present invention provides a patch comprising a backing and an adhesive layer laminated on one side of the backing, wherein the adhesive layer comprises asenapine or a pharmaceutically acceptable salt thereof, an adhesive base and a low molecular weight amine.